Response to: Harrison Ts, Macallan DC, Rayner CFJ, Wansborough-Jones M. Treatment of tuberculosis in HIV-infected individuals AIDS 2002EDWARDS, Simon; POZNIAK, Anton L; MILLER, Rob et al.AIDS (London). 2002, Vol 16, Num 11, pp 1571-1572, issn 0269-9370Article

Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agentsCOYNE, Katherine M; POZNIAK, Anton L; LAMORDE, Mohammed et al.AIDS (London). 2009, Vol 23, Num 4, pp 437-446, issn 0269-9370, 10 p.Article

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING studyCAHN, Pedro; POZNIAK, Anton L; HAGINS, Debbie et al.Lancet (British edition). 2013, Vol 382, Num 9893, pp 700-708, issn 0140-6736, 9 p.Article

Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosingDICKINSON, Laura; BOFFITO, Marta; KHOO, Saye H et al.Journal of antimicrobial chemotherapy (Print). 2008, Vol 62, Num 1, pp 161-167, issn 0305-7453, 7 p.Article

The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patientsGALLANT, Joel E; WINSTON, Jonathan A; DEJESUS, Edwin et al.AIDS (London). 2008, Vol 22, Num 16, pp 2155-2163, issn 0269-9370, 9 p.Article

Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individualsDICKINSON, Laura; BOFFITO, Marta; BACK, David J et al.Journal of antimicrobial chemotherapy (Print). 2008, Vol 62, Num 6, pp 1344-1355, issn 0305-7453, 12 p.Article

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virusDORE, Gregory J; COOPER, David A; POZNIAK, Anton L et al.The Journal of infectious diseases. 2004, Vol 189, Num 7, pp 1185-1192, issn 0022-1899, 8 p.Article

An open-label assessment of TMC 125: a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistanceGAZZARD, Brian G; POZNIAK, Anton L; VANT'KLOOSTER, Gerben A. E et al.AIDS (London). 2003, Vol 17, Num 18, pp F49-F54, issn 0269-9370Article

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapyDEAN, Gillian L; EDWARDS, Simon G; DE RUITER, Annemiek et al.AIDS (London). 2002, Vol 16, Num 1, pp 75-83, issn 0269-9370Article

The development of an expert system to predict virological response to HIV therapy as part of an online treatment support toolREVELL, Andrew D; DECHAO WANG; BOYD, Mark A et al.AIDS (London). 2011, Vol 25, Num 15, pp 1855-1863, issn 0269-9370, 9 p.Article

Single-and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patientsKAKUDA, Thomas N; SCHÖLLER-GYÜRE, Monika; HOETELMANS, Richard M. W et al.Antiviral therapy (London). 2008, Vol 13, Num 5, pp 655-661, issn 1359-6535, 7 p.Article

The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosineSPROAT, Michael; POZNIAK, Anton L; PEETERS, Monika et al.Antiviral therapy (London). 2005, Vol 10, Num 2, pp 357-361, issn 1359-6535, 5 p.Article

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: A randomized trialSQUIRES, Kathleen; POZNIAK, Anton L; COAKLEY, Dion F et al.Annals of internal medicine. 2003, Vol 139, Num 5, pp 313-320, issn 0003-4819, 8 p., 1Article

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trialPOZNIAK, Anton L; MORALES-RAMIREZ, Javier; BOVEN, Katia et al.AIDS (London). 2010, Vol 24, Num 1, pp 55-65, issn 0269-9370, 11 p.Article

Effects of Different Meal Compositions and Fasted State on the Oral Bioavailability of EtravirineSCHÖLLER-GYÜRE, Monika; BOFFITO, Marta; POZNIAK, Anton L et al.Pharmacotherapy. 2008, Vol 28, Num 10, pp 1215-1222, issn 0277-0008, 8 p.Article

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trialGALLANT, Joel E; STASZEWSKI, Schlomo; POZNIAK, Anton L et al.JAMA, the journal of the American Medical Association. 2004, Vol 292, Num 2, pp 191-201, issn 0098-7484, 11 p.Article

A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjectsPOZNIAK, Anton L; BOFFITO, Marta; RUSSELL, Deborah et al.British journal of clinical pharmacology. 2008, Vol 65, pp 54-59, issn 0306-5251, 6 p., SUP1Article

Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteersWINSTON, Alan; BACK, David; FLETCHER, Carl et al.AIDS (London). 2006, Vol 20, Num 10, pp 1401-1406, issn 0269-9370, 6 p.Article

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIVGALLANT, Joel E; DEJESUS, Edwin; TOOLE, John J et al.The New England journal of medicine. 2006, Vol 354, Num 3, pp 251-260, issn 0028-4793, 10 p.Article

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimenBOFFITO, Marta; KUROWSKI, Michael; KRUSE, Guido et al.AIDS (London). 2004, Vol 18, Num 9, pp 1291-1297, issn 0269-9370, 7 p.Article

Long-Term Efficacy, Safety, and Tolerability of Rilpivirine (RPV, TMC278) in HIV Type 1-Infected Antiretroviral-Naive Patients: Week 192 Results from a Phase llb Randomized TrialWILKIN, Aimee; POZNIAK, Anton L; MORALES-RAMIREZ, Javier et al.AIDS research and human retroviruses. 2012, Vol 28, Num 5, pp 437-446, issn 0889-2229, 10 p.Article

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients : 144-Week AnalysisARRIBAS, Jose R; POZNIAK, Anton L; TOOLE, John J et al.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 47, Num 1, pp 74-78, issn 1525-4135, 5 p.Article

Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-Using virus reservoirWESTBY, Mike; LEWIS, Marilyn; WHITCOMB, Jeannette et al.Journal of virology. 2006, Vol 80, Num 10, pp 4909-4920, issn 0022-538X, 12 p.Article

Short-term antiviral activity of TMC278 : a novel NNRTI - in treatment-naive HIV-1-infected subjectsGOEBEL, Frank; YAKOVLEV, Alexy; POZNIAK, Anton L et al.AIDS (London). 2006, Vol 20, Num 13, pp 1721-1726, issn 0269-9370, 6 p.Article

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients : Virologic, immunologic, and morphologic changes-A 96-week analysisPOZNIAK, Anton L; GALLANT, Joel E; CHENG, Andrew K et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 43, Num 5, pp 535-540, issn 1525-4135, 6 p.Article